{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T17:23:40Z","timestamp":1787592220405,"version":"build-2736575974"},"reference-count":125,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009687","name":"Uniwersytet Medyczny im. Piast\u00f3w Slaskich we Wroclawiu","doi-asserted-by":"publisher","award":["SUBZ.A130.26.050"],"award-info":[{"award-number":["SUBZ.A130.26.050"]}],"id":[{"id":"10.13039\/501100009687","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p>\n                    Gastric acid is essential for digestion, host defense, and maintenance of gastrointestinal homeostasis; however, its excessive or inappropriate secretion contributes to the development and progression of several acid-related disorders. Proton pump inhibitors (PPIs) have remained the cornerstone of acid-suppressive therapies for more than four decades owing to their potent blockade of gastric H\n                    <jats:sup>+<\/jats:sup>\n                    \/K\n                    <jats:sup>+<\/jats:sup>\n                    -ATPases. This review provides a comprehensive overview of the pharmacological properties, clinical applications, and current limitations of the most widely used PPIs, including omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole, and rabeprazole. Particular emphasis is placed on their role in the management of\n                    <jats:italic>Helicobacter pylori<\/jats:italic>\n                    infection, a strong risk factor for the development of severe gastric diseases and one of the most clinically important indications for PPI-based antibiotic therapy. Beyond elevating intragastric pH to enhance antibiotic stability and efficacy, accumulating evidence indicates that PPIs exert direct antibacterial activity against\n                    <jats:italic>H. pylori<\/jats:italic>\n                    and may act synergistically with selected antibiotics. The review also discusses emerging evidence for interindividual variability in PPI metabolism, drug-drug interactions, and concerns regarding long-term adverse effects of the current treatments. Finally, it highlights potassium-competitive acid blockers (P-CABs), a newer class of acid-suppressive agents that provide sustained acid inhibition and represent a promising alternative to PPI-based regimens for\n                    <jats:italic>H. pylori<\/jats:italic>\n                    eradication.\n                  <\/jats:p>","DOI":"10.3389\/fmicb.2026.1947561","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T16:27:05Z","timestamp":1787588825000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond acid suppression: the multifaceted role of proton pump inhibitors in Helicobacter pylori eradication"],"prefix":"10.3389","volume":"17","author":[{"given":"Paulina","family":"Sroczy\u0144ska","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Diabetology and Internal Medicine, T. Marciniak Lower Silesian Specialist Hospital - Emergency Medicine Center","place":["Wroc\u0142aw, Poland"]},{"name":"Department of Microbiology, Faculty of Medicine, Wroc\u0142aw Medical University","place":["Wroc\u0142aw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Krzy\u017cek","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Faculty of Medicine, Wroc\u0142aw Medical University","place":["Wroc\u0142aw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/BF01699986","article-title":"In vitro activity of ebrotidine, ranitidine, omeprazole, lansoprazole, and bismuth citrate against clinical isolates of Helicobacter pylori.","volume":"17","author":"Alarc\u00f3n","year":"1998","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/J.1365-2125.1990.TB03679.X","article-title":"Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects.","volume":"29","author":"Andersson","year":"1990","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1046\/J.1365-2036.2001.01087.X","article-title":"Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole.","volume":"15","author":"Andersson","year":"2001","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.3390\/MEDICINA61091569","article-title":"Proton pump inhibitors (PPIs)\u2014an evidence-based review of indications, efficacy, harms, and deprescribing.","volume":"61","author":"Andrawes","year":"2025","journal-title":"Medicina"},{"key":"B5","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/BS.PODRM.2020.07.003","article-title":"Rabeprazole: a comprehensive profile.","volume":"46","author":"Bakheit","year":"2021","journal-title":"Profiles Drug Subst. Excip. Relat. Methodol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1111\/J.1365-2036.2011.04874.X","article-title":"Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection.","volume":"34","author":"Bavishi","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/J.JACASI.2025.10.028","article-title":"Revisiting the proton pump inhibitor\u2013clopidogrel conundrum.","volume":"6","author":"Bavishi","year":"2026","journal-title":"JACC"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e13148","DOI":"10.1111\/HEL.13148","article-title":"Efficacy and safety of vonoprazan in dual\/triple\/quadruple regimens both in first-line and rescue therapy for Helicobacter pylori eradication: a systematic review with meta-analysis.","volume":"29","author":"Benito","year":"2024","journal-title":"Helicobacter"},{"key":"B9","doi-asserted-by":"publisher","first-page":"22438","DOI":"10.1074\/JBC.272.36.22438","article-title":"Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents.","volume":"272","author":"Besancon","year":"1997","journal-title":"J. Biol. Chem."},{"key":"B10","doi-asserted-by":"publisher","first-page":"769","DOI":"10.2165\/00002018-200629090-00002","article-title":"Pharmacokinetic drug interaction profiles of proton pump inhibitors.","volume":"29","author":"Blume","year":"2006","journal-title":"Drug Saf."},{"key":"B11","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1053\/HUPA.2000.7637","article-title":"Parietal cell protrusions and fundic gland cysts during omeprazole maintenance treatment.","volume":"31","author":"Cats","year":"2000","journal-title":"Hum. Pathol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3109\/00365528909091241","article-title":"Omeprazole: pharmacokinetics and metabolism in man.","volume":"166","author":"Cederberg","year":"1989","journal-title":"Scand. J. Gastroenterol. Suppl."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1093\/JAC\/34.6.1025","article-title":"Additive effect of clarithromycin combined with 14-hydroxy clarithromycin, erythromycin, amoxycillin, metronidazole or omeprazole against Helicobacter pylori.","volume":"34","author":"Cederbrant","year":"1994","journal-title":"J. Antimicrob. Chemother."},{"key":"B14","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/J.JARE.2025.09.055","article-title":"Helicobacter pylori-derived outer membrane vesicles: pathogenic roles, microbiota interactions, and biomedical applications.","volume":"84","author":"Chen","year":"2026","journal-title":"J. Adv. Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3961\/jpmph.24.357","article-title":"Utilization of acid suppressants after withdrawal of ranitidine in Korea: an interrupted time series analysis.","volume":"58","author":"Choi","year":"2025","journal-title":"J. Prevent. Med. Public Health"},{"key":"B16","doi-asserted-by":"publisher","first-page":"813","DOI":"10.2165\/00003088-200241110-00003","article-title":"Mechanisms of clinically relevant drug interactions associated with tacrolimus.","volume":"41","author":"Christians","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.3390\/microorganisms13081955","article-title":"Association of Helicobacter pylori as an extragastric reservoir in the oral cavity with oral diseases in patients with and without gastritis\u2014a systematic review.","volume":"13","author":"Cuba","year":"2025","journal-title":"Microorganisms"},{"key":"B18","doi-asserted-by":"publisher","first-page":"913","DOI":"10.2165\/00003088-200241120-00002","article-title":"Clinical significance of the cytochrome P450 2C19 genetic polymorphism.","volume":"41","author":"Desta","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"B19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.5114\/pg.2022.116673","article-title":"Potassium-competitive acid blockers, a new therapeutic class, and their role in acid-related diseases: a narrative review.","volume":"18","author":"Domingues","year":"2023","journal-title":"Gastroenterol. Rev."},{"key":"B20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.56782\/PPS.226","article-title":"Proton pump inhibitors: prolonged intake and adverse effects.","volume":"22","author":"Dominiczak","year":"2024","journal-title":"Prospect. Pharmaceut. Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e12945","DOI":"10.1111\/HEL.12945","article-title":"Transmission routes and patterns of Helicobacter pylori.","volume":"28","author":"Duan","year":"2023","journal-title":"Helicobacter"},{"key":"B22","first-page":"112","article-title":"Small intestinal bacterial overgrowth: a comprehensive review.","volume":"3","author":"Dukowicz","year":"2007","journal-title":"Gastroenterol. Hepatol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/S12664-023-01428-7","article-title":"Guidelines on optimizing the use of proton pump inhibitors: PPI stewardship.","volume":"42","author":"Dutta","year":"2023","journal-title":"Indian J. Gastroenterol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.2169\/INTERNALMEDICINE.49.4064","article-title":"Patterns and predictors of proton pump inhibitor overuse among academic and non-academic hospitalists.","volume":"49","author":"Eid","year":"2010","journal-title":"Intern. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1080\/17425255.2018.1461835","article-title":"Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine.","volume":"14","author":"El Rouby","year":"2018","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B26","unstructured":"European Medicines Agency Decision P\/0277\/2024 of 14 August 2024 on the Acceptance of a Modification of an Agreed Paediatric Investigation Plan for Vonoprazan (EMEA-002703-PIP01-19-M01).\n          \n          2024"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1111\/J.1572-0241.2000.02233.X","article-title":"Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Raberprazole Study Group.","volume":"95","author":"Farley","year":"2000","journal-title":"Am. J. Gastroenterol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/290159A0","article-title":"Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+ + K+) ATPase.","volume":"290","author":"Fellenius","year":"1981","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3390\/TOXINS8060173","article-title":"An overview of Helicobacter pylori VacA toxin biology.","volume":"8","author":"Foegeding","year":"2016","journal-title":"Toxins"},{"key":"B30","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/J.ACVD.2013.09.002","article-title":"Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers.","volume":"106","author":"Funck-Brentano","year":"2013","journal-title":"Arch. Cardiovasc. Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1159\/000502287","article-title":"Dual therapy with vonoprazan and amoxicillin is as effective as triple therapy with vonoprazan, amoxicillin and clarithromycin for eradication of Helicobacter pylori.","volume":"101","author":"Furuta","year":"2020","journal-title":"Digestion"},{"key":"B32","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/S002280050111","article-title":"Pharmacokinetics and absolute bioavailability of lansoprazole.","volume":"50","author":"Gerloff","year":"1996","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1111\/J.1440-1746.1994.TB01292.X","article-title":"How Helicobacter pylori acquired its name, and how it overcomes gastric defence mechanisms.","volume":"9","author":"Goodwin","year":"1994","journal-title":"J. Gastroenterol. Hepatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/bcpt.13023","article-title":"Side effects of long-term proton pump inhibitor use: a review.","volume":"123","author":"Haastrup","year":"2018","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2183\/PJAB.93.013","article-title":"Structure and function of Helicobacter pylori CagA, the first-identified bacterial protein involved in human cancer.","volume":"93","author":"Hatakeyama","year":"2017","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1111\/J.1572-0241.2006.00839.X","article-title":"Magnitude and economic impact of inappropriate use of stress ulcer prophylaxis in non-ICU hospitalized patients.","volume":"101","author":"Heidelbaugh","year":"2006","journal-title":"Am. J. Gastroenterol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1001\/ARCHINTE.165.10.1095","article-title":"Systematic overview of warfarin and its drug and food interactions.","volume":"165","author":"Holbrook","year":"2005","journal-title":"Arch. Intern. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1007\/S00535-010-0207-7","article-title":"Incidence and risk factor of fundic gland polyp and hyperplastic polyp in long-term proton pump inhibitor therapy: a prospective study in Japan.","volume":"45","author":"Hongo","year":"2010","journal-title":"J. Gastroenterol."},{"key":"B39","first-page":"17S","article-title":"Optimizing the pharmacology of acid control in acid-related disorders.","volume":"92","author":"Howden","year":"1997","journal-title":"Am. J. Gastroenterol"},{"key":"B40","first-page":"159","article-title":"pH, healing rate and symptom relief in acid-related diseases.","volume":"69","author":"Huang","year":"1996","journal-title":"Yale J. Biol. Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3109\/00365528809099128","article-title":"The protective role of gastric acid.","volume":"23","author":"Hunt","year":"1988","journal-title":"Scand. J. Gastroenterol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/J.1365-2036.2008.03725.X","article-title":"Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z.","volume":"28","author":"Hunt","year":"2008","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B43","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1007\/S11938-018-0206-Y","article-title":"Potent acid suppression with PPIs and P-CABs: What\u2019s New?","volume":"16","author":"Hunt","year":"2018","journal-title":"Curr. Treat. Opt. Gastroenterol."},{"key":"B44","first-page":"1","article-title":"Schistosomes, liver flukes and Helicobacter pylori.","volume":"61","year":"1994","journal-title":"IARC Monogr. Eval. Carcinog. Risks Hum."},{"key":"B45","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1128\/AAC.35.3.490","article-title":"Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori.","volume":"35","author":"Iwahi","year":"1991","journal-title":"Antimicrob. Agents Chemother."},{"key":"B46","doi-asserted-by":"publisher","first-page":"425","DOI":"10.32383\/farmpol\/142110","article-title":"T E R A P I A I L E K I Znaczenie lek\u00f3w zoboj\u0119tniaj\u0105cych w chorobach zwi\u0105zanych z nadmiernym wydzielaniem kwasu solnego.","volume":"77","author":"Janiaczyk","year":"2021","journal-title":"Farm. Pol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/APT.13121","article-title":"Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects.","volume":"41","author":"Jenkins","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B48","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/J.MIB.2017.11.019","article-title":"Colonization, localization, and inflammation: the roles of H. pylori chemotaxis in vivo.","volume":"41","author":"Johnson","year":"2017","journal-title":"Curr. Opin. Microbiol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/apt.14130","article-title":"Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication.","volume":"46","author":"Jung","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B50","first-page":"7","article-title":"Proton pump inhibitor-treated H. pylori adjust cell envelope fatty acid and cholesterol content to survive.","volume":"23","author":"Kadkhodaei","year":"2020","journal-title":"Arch. Iran. Med."},{"key":"B51","unstructured":"Kane\n              S. P.\n            \n          \n          Proton Pump Inhibitor, ClinCalc DrugStats Database.\n          \n          2025"},{"key":"B52","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/BF03189822","article-title":"Comparative pharmacokinetic\/pharmacodynamic analysis of proton pump inhibitors omeprazole, lansoprazole and pantoprazole, in humans.","volume":"23","author":"Katashima","year":"1998","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"B53","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1128\/AAC.44.2.458-461.2000","article-title":"In vitro activities of rabeprazole, a novel proton pump inhibitor, and its thioether derivative alone and in combination with other antimicrobials against recent clinical isolates of Helicobacter pylori.","volume":"44","author":"Kawakami","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"B54","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/J.CANLET.2010.07.014","article-title":"Helicobacter pylori in the pathogenesis of gastric cancer and gastric lymphoma.","volume":"305","author":"Kim","year":"2010","journal-title":"Cancer Lett."},{"key":"B55","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/J.1600-0773.2004.PTO950102.X","article-title":"CYP2C19 polymorphism and proton pump inhibitors.","volume":"95","author":"Klotz","year":"2004","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"12222","DOI":"10.3390\/IJMS252212222","article-title":"Helicobacter pylori efflux pumps: a double-edged sword in antibiotic resistance and biofilm formation.","volume":"25","author":"Krzy\u017cek","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B57","doi-asserted-by":"publisher","first-page":"184","DOI":"10.3390\/PATHOGENS9030184","article-title":"Transformation of Helicobacter pylori into coccoid forms as a challenge for research determining activity of antimicrobial substances.","volume":"9","author":"Krzy\u017cek","year":"2020","journal-title":"Pathogens"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/PATHOGENS9121062","article-title":"Biofilm formation as a complex result of virulence and adaptive responses of Helicobacter pylori.","volume":"9","author":"Krzy\u017cek","year":"2020","journal-title":"Pathogens"},{"key":"B59","doi-asserted-by":"publisher","first-page":"289","DOI":"10.20452\/pamw.2790","article-title":"Overuse of proton pump inhibitors.","volume":"125","author":"Ksi\u0105dzyna","year":"2015","journal-title":"Pol. Arch. Intern. Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"e2215512120","DOI":"10.1073\/pnas.2215512120","article-title":"The human proton pump inhibitors inhibit Mycobacterium tuberculosis rifampicin efflux and macrophage-induced rifampicin tolerance.","volume":"120","author":"Lake","year":"2023","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B61","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1124\/dmd.32.8.821","article-title":"Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.","volume":"32","author":"Li","year":"2004","journal-title":"Drug Metab. Dispos."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1002\/CPT.2015","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) Guideline for CYP2C19 and proton pump inhibitor dosing.","volume":"109","author":"Lima","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.3390\/MICROORGANISMS13061227","article-title":"Antimicrobial and anti-efflux machinery of FDA-approved proton pump inhibitors and vitamins against Klebsiella pneumoniae and Pseudomonas aeruginosa.","volume":"13","author":"Lutfi","year":"2025","journal-title":"Microorganisms"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1739284","DOI":"10.3389\/fmed.2025.1739284","article-title":"Vonoprazan-amoxicillin dual therapy vs. proton pump inhibitor based dual therapy for Helicobacter pylori eradication: a meta-analysis.","volume":"12","author":"Lv","year":"2026","journal-title":"Front. Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/S41572-023-00431-8","article-title":"Helicobacter pylori infection.","volume":"9","author":"Malfertheiner","year":"2023","journal-title":"Nat. Rev. Dis. Primers"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/S0140-6736(09)60938-7","article-title":"Peptic ulcer disease.","volume":"374","author":"Malfertheiner","year":"2009","journal-title":"Lancet"},{"key":"B67","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/NRGASTRO.2017.117","article-title":"Proton-pump inhibitors: understanding the complications and risks.","volume":"14","author":"Malfertheiner","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1136\/gutjnl-2022-327745","article-title":"Management of Helicobacter pylori infection: the Maastricht VI\/Florence consensus report.","volume":"71","author":"Malfertheiner","year":"2022","journal-title":"Gut"},{"key":"B69","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/jac\/41.suppl_2.29","article-title":"Synergic interactions of macrolides and proton-pump inhibitors against Helicobacter pylori: a comparative in-vitro study.","volume":"41","author":"Malizia","year":"1998","journal-title":"J. Antimicrob. Chemother."},{"key":"B70","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1111\/APT.13800","article-title":"Systematic review with meta-analysis: fundic gland polyps and proton pump inhibitors.","volume":"44","author":"Martin","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B71","doi-asserted-by":"publisher","first-page":"656439","DOI":"10.3389\/fmolb.2021.656439","article-title":"Adhesion of Helicobacter species to the human gastric mucosa: a deep look into glycans role.","volume":"8","author":"Matos","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"B72","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/J.1365-2036.2012.05211.X","article-title":"Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection.","volume":"36","author":"McNicholl","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1128\/AAC.40.6.1531","article-title":"Oxygen concentration influences proton pump inhibitor activity against Helicobacter pylori in vitro.","volume":"40","author":"Midolo","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"B74","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1136\/JCP.51.3.220","article-title":"Omeprazole may exert both a bacteriostatic and a bacteriocidal effect on the growth of Helicobacter pylori (NCTC 11637) in vitro by inhibiting bacterial urease activity.","volume":"51","author":"Mirshahi","year":"1998","journal-title":"J. Clin. Pathol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3238\/arztebl.2016.0477","article-title":"The indications, applications, and risks of proton pump inhibitors.","volume":"113","author":"M\u00f6ssner","year":"2016","journal-title":"Dtsch. Arztebl. Int"},{"key":"B76","doi-asserted-by":"publisher","first-page":"349","DOI":"10.22037\/ghfbb.v14i4.2178","article-title":"Candida colonization of the esophagus and gastric mucosa; a comparison of patients taking proton pump inhibitors and those taking histamine receptor antagonist drugs.","volume":"14","author":"Mottaghi","year":"2021","journal-title":"Gastroenterol. Hepatol. Bed Bench"},{"key":"B77","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/CPDD.1009","article-title":"The effect of food on the pharmacokinetics of the potassium-competitive acid blocker vonoprazan.","volume":"11","author":"Mulford","year":"2022","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"B78","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1128\/AAC.37.4.769","article-title":"Potent inhibitory action of the gastric proton pump inhibitor lansoprazole against urease activity of Helicobacter pylori: unique action selective for H. pylori cells.","volume":"37","author":"Nagata","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"B79","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1128\/AAC.39.2.567","article-title":"Inhibitory action of lansoprazole and its analogs against Helicobacter pylori: inhibition of growth is not related to inhibition of urease.","volume":"39","author":"Nagata","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"B80","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1097\/00004836-199506001-00008","article-title":"Antibacterial properties of lansoprazole alone and in combination with antimicrobial agents against Helicobacter pylori.","volume":"20","author":"Nakao","year":"1995","journal-title":"J. Clin. Gastroenterol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1046\/J.1523-5378.1998.08024.X","article-title":"Growth inhibitory and bactericidal activities of lansoprazole compared with those of omeprazole and pantoprazole against Helicobacter pylori.","volume":"3","author":"Nakao","year":"1998","journal-title":"Helicobacter"},{"key":"B82","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.1111\/J.1572-0241.2000.03259.X","article-title":"Overuse of acid-suppressive therapy in hospitalized patients.","volume":"95","author":"Nardino","year":"2000","journal-title":"Am. J. Gastroenterol."},{"key":"B83","volume-title":"Physiology, Gastrointestinal.","author":"Ogobuiro","year":"2023"},{"key":"B84","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/NRD1010","article-title":"A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole.","volume":"2","author":"Olbe","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1002\/PDS.4043","article-title":"Proton pump inhibitor prescribing patterns in the UK: a primary care database study.","volume":"25","author":"Othman","year":"2016","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B86","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/UEG2.12476","article-title":"Role of proton pump inhibitors dosage and duration in Helicobacter pylori eradication treatment: results from the European Registry on H. pylori management.","volume":"12","author":"Pab\u00f3n-Carrasco","year":"2023","journal-title":"U. Eur. Gastroenterol. J."},{"key":"B87","doi-asserted-by":"publisher","first-page":"23333928241241220","DOI":"10.1177\/23333928241241220","article-title":"Proton pump inhibitors in germany: status quo of a growing market.","volume":"11","author":"Plehhova","year":"2024","journal-title":"Health Serv. Res. Manag. Epidemiol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1655102","DOI":"10.3389\/fphys.2025.1655102","article-title":"Potassium-competitive acid blockers and advances in the management of patients with acid-related diseases: a narrative review.","volume":"16","author":"Qiao","year":"2025","journal-title":"Front. Physiol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1358\/DOT.1999.35.10.561695","article-title":"Pharmacokinetics and metabolism of the proton pump inhibitor pantoprazole in man.","volume":"35","author":"Radhofer-Welte","year":"1999","journal-title":"Drugs Today"},{"key":"B90","doi-asserted-by":"publisher","first-page":"101","DOI":"10.5688\/AJ7005101","article-title":"The chemically elegant proton pump inhibitors.","volume":"70","author":"Roche","year":"2006","journal-title":"Am. J. Pharm. Educ."},{"key":"B91","first-page":"S35","article-title":"Improving on PPI-based therapy of GORD.","volume":"13","author":"Sachs","year":"2001","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"68S","DOI":"10.1592\/PHCO.23.13.68S.31931","article-title":"Physiology of the parietal cell and therapeutic implications.","volume":"23","author":"Sachs","year":"2003","journal-title":"Pharmacotherapy"},{"key":"B93","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/J.1365-2036.2006.02943.X","article-title":"Review article: the clinical pharmacology of proton pump inhibitors.","volume":"23","author":"Sachs","year":"2006","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B94","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/HEL.12246","article-title":"Negative effect of proton-pump inhibitors (PPIs) on Helicobacter pylori growth, morphology, and urease test and recovery after PPI removal \u2013 an in vitro study.","volume":"21","author":"Saniee","year":"2016","journal-title":"Helicobacter"},{"key":"B95","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/J.COPH.2008.09.004","article-title":"Proton pump inhibitors: the beginning of the end or the end of the beginning?","volume":"8","author":"Scarpignato","year":"2008","journal-title":"Curr. Opin. Pharmacol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/S11938-020-00330-X","article-title":"Acid suppressant therapy: a step forward with potassium-competitive acid blockers.","volume":"19","author":"Scarpignato","year":"2021","journal-title":"Curr. Treat. Opt. Gastroenterol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/S11894-024-00939-3","article-title":"Potassium-competitive acid blockers: current clinical use and future developments.","volume":"26","author":"Scarpignato","year":"2024","journal-title":"Curr. Gastroenterol. Rep."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.12688\/f1000research.8598.1","article-title":"The role of acid inhibition in Helicobacter pylori eradication.","volume":"5","author":"Scott","year":"2016","journal-title":"F1000Res"},{"key":"B99","first-page":"72","volume-title":"Truncal Vagotomy: Atlas of Surgical Techniques for the Upper GI Tract and Small Bowel.","author":"Seeras","year":"2022"},{"key":"B100","doi-asserted-by":"publisher","first-page":"7800","DOI":"10.1021\/JA049607W","article-title":"Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors.","volume":"126","author":"Shin","year":"2004","journal-title":"J. Am. Chem. Soc."},{"key":"B101","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/S00424-008-0495-4","article-title":"The gastric HK-ATPase: structure, function, and inhibition.","volume":"457","author":"Shin","year":"2008","journal-title":"Pflugers Arch."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1053\/gast.2002.36593","article-title":"Restoration of acid secretion following treatment with proton pump inhibitors.","volume":"123","author":"Shin","year":"2002","journal-title":"Gastroenterology"},{"key":"B103","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1007\/S11894-008-0098-4","article-title":"Pharmacology of proton pump inhibitors.","volume":"10","author":"Shin","year":"2008","journal-title":"Curr. Gastroenterol. Rep."},{"key":"B104","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s40265-023-01991-5","article-title":"Vonoprazan: a review in Helicobacter pylori infection.","volume":"84","author":"Shirley","year":"2024","journal-title":"Drugs"},{"key":"B105","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1128\/AAC.41.8.1797","article-title":"Basis for the selective antibacterial activity in vitro of proton pump inhibitors against Helicobacter spp.","volume":"41","author":"Sj\u00f8str\u00f8m","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"B106","doi-asserted-by":"publisher","first-page":"191","DOI":"10.5114\/pg.2015.56109","article-title":"Dexlansoprazole \u2013 a new-generation proton pump inhibitor.","volume":"4","author":"Skrzyd\u0142o-Radoma\u0144ska","year":"2015","journal-title":"Gastroenterol. Rev."},{"key":"B107","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1177\/26345161211021766","article-title":"Proton pump inhibitors in 2021: pros, cons, and everything in between.","volume":"1","author":"Sloan","year":"2021","journal-title":"Foregut"},{"key":"B108","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1159\/000226426","article-title":"In vitro antagonism of rabeprazole and metronidazole upon clinical isolates of Helicobacter pylori.","volume":"55","author":"Soto","year":"2009","journal-title":"Chemotherapy"},{"key":"B109","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.3390\/PHARMACEUTICS14102043","article-title":"Formulation of dosage forms with proton pump inhibitors: state of the art, challenges and future perspectives.","volume":"14","author":"Srebro","year":"2022","journal-title":"Pharmaceutics"},{"key":"B110","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1046\/J.1365-2036.2000.00788.X","article-title":"Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors.","volume":"14","author":"Stedman","year":"2000","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B111","doi-asserted-by":"publisher","first-page":"27","DOI":"10.5009\/GNL15502","article-title":"25 years of proton pump inhibitors: a comprehensive review.","volume":"11","author":"Strand","year":"2016","journal-title":"Gut Liver"},{"key":"B112","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1136\/GUTJNL-2019-319954","article-title":"Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan.","volume":"69","author":"Suzuki","year":"2020","journal-title":"Gut"},{"key":"B113","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1046\/J.1365-2036.1999.00020.X","article-title":"Review article: the pharmacokinetics of rabeprazole in health and disease.","volume":"13","author":"Swan","year":"1999","journal-title":"Aliment. Pharmacol. Therapeut. Suppl."},{"key":"B114","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1248\/BPB.18.1053","article-title":"Helicobacter pylori urease inhibition by rabeprazole, a proton pump inhibitor.","volume":"18","author":"Tsuchiya","year":"1995","journal-title":"Biol. Pharm. Bull."},{"key":"B115","volume-title":"NDA Approval Letter: Voquezna (vonoprazan) Tablets, NDA 215151.","year":"2023"},{"key":"B116","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1128\/AAC.01306-05","article-title":"Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.","volume":"51","author":"Vidaillac","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"B117","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/S40264-014-0144-0","article-title":"Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update.","volume":"37","author":"Wedemeyer","year":"2014","journal-title":"Drug Saf."},{"key":"B118","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1007\/BF01537246","article-title":"Tolerance to oral H2-receptor antagonists.","volume":"35","author":"Wilder-Smith","year":"1990","journal-title":"Dig. Dis. Sci."},{"key":"B119","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1128\/CMR.00011-10","article-title":"Helicobacter pylori and gastric cancer: factors that modulate disease risk.","volume":"23","author":"Wroblewski","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"key":"B120","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/00008571-199910000-00001","article-title":"Allelic, genotypic and phenotypic distributions of S-mephenytoin 4\u2019-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world.","volume":"9","author":"Xie","year":"1999","journal-title":"Pharmacogenetics"},{"key":"B121","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/NRGASTRO.2010.154","article-title":"Mechanisms of disease: Helicobacter pylori virulence factors.","volume":"7","author":"Yamaoka","year":"2010","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B122","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1080\/00498254.2016.1203505","article-title":"In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker.","volume":"47","author":"Yamasaki","year":"2017","journal-title":"Xenobiotica"},{"key":"B123","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1007\/S12325-017-0532-9","article-title":"A review of the novel application and potential adverse effects of proton pump inhibitors.","volume":"34","author":"Yu","year":"2017","journal-title":"Adv. Ther."},{"key":"B124","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/J.PHARMTHERA.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"B125","doi-asserted-by":"publisher","first-page":"e072793","DOI":"10.1136\/bmjopen-2023-072793","article-title":"Evolution of proton pump inhibitor prescribing from 2017 to 2021 at 14 secondary and tertiary hospitals in China:a multicentre cross-sectional study.","volume":"13","author":"Zeng","year":"2023","journal-title":"BMJ Open"}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1947561\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T16:27:10Z","timestamp":1787588830000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1947561\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":125,"alternative-id":["10.3389\/fmicb.2026.1947561"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2026.1947561","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"article-number":"1947561"}}